AI Article Synopsis
Article Abstract
Background: Though clinically similar, Ebola virus disease and Marburg virus disease are caused by different viruses. Of the 30 documented outbreaks of these diseases in sub-Saharan Africa, eight were major outbreaks (≥200 cases; five caused by Zaire ebolavirus [EBOV], two by Sudan ebolavirus [SUDV], and one by Marburg virus [MARV]). Our purpose is to develop a multivalent vaccine regimen protecting against each of these filoviruses. This first-in-human study assessed the safety and immunogenicity of several multivalent two-dose vaccine regimens that contain Ad26.Filo and MVA-BN-Filo.
Methods: Ad26.Filo combines three vaccines encoding the glycoprotein (GP) of EBOV, SUDV, and MARV. MVA-BN-Filo is a multivalent vector encoding EBOV, SUDV, and MARV GPs, and Taï Forest nucleoprotein. This Phase 1, randomized, double-blind, placebo-controlled study enrolled healthy adults (18-50 years) into four groups, randomized 5:1 (active:placebo), to assess different Ad26.Filo and MVA-BN-Filo vaccine directionality and administration intervals. The primary endpoint was safety; immune responses against EBOV, SUDV, and MARV GPs were also assessed.
Results: Seventy-two participants were randomized, and 60 (83.3%) completed the study. All regimens were well tolerated with no deaths or vaccine-related serious adverse events (AEs). The most frequently reported solicited local AE was injection site pain/tenderness. Solicited systemic AEs most frequently reported were headache, fatigue, chills, and myalgia; most solicited AEs were Grade 1-2. Solicited/unsolicited AE profiles were similar between regimens. Twenty-one days post-dose 2, 100% of participants on active regimen responded to vaccination and exhibited binding antibodies against EBOV, SUDV, and MARV GPs; neutralizing antibody responses were robust against EBOV (85.7-100%), but lower against SUDV (35.7-100%) and MARV (0-57.1%) GPs. An Ad26.Filo booster induced a rapid further increase in humoral responses.
Conclusion: This study demonstrates that heterologous two-dose vaccine regimens with Ad26.Filo and MVA-BN-Filo are well tolerated and immunogenic in healthy adults.
Clinicaltrials.gov: NCT02860650.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534391 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0274906 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
High Seroreactivities to Orthoebolaviruses in Rural Cameroon: A Case-Control Study on Nonhuman Primate Bites and a Cross-sectional Survey in Rural Populations.
J Infect Dis
November 2024
Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, Université de Paris Cité, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 3569, Paris.
Article Synopsis
- - High seroreactivities to Ebola (EBOV) and Sudan (SUDV) orthoebolavirus antigens were found in rural populations of Cameroon, particularly among Pygmies, despite no reported outbreaks.
- - The study did not find a direct link between the risk of NHP (nonhuman primates) bites and seroreactivity, but indicated that exposure may vary among different ethnic groups.
- - These findings suggest a possible silent circulation of orthoebolaviruses or other unknown filoviruses in forested regions, emphasizing the need for increased surveillance and research in these areas.
Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.
Front Immunol
July 2024
Oxford Vaccine Group, Department of Pediatrics, University of Oxford, Oxford, United Kingdom.
Article Synopsis
- Outbreaks of Ebolaviruses, like Sudanvirus in Uganda in 2022, highlight the need for vaccines that target more than just the Zaire ebolavirus, which is currently the only one in use.
- A new vaccine regimen, Ad26.ZEBOV/MVA-BN-Filo, was developed and tested in the EBL2001 clinical trial, aiming to enhance immunity against various Ebolaviruses.
- Researchers sequenced B cell receptors from trial participants and created a database of Ebolavirus-specific antibodies, revealing important patterns in immune responses and demonstrating the potential for computational techniques to analyze immune repertoires effectively.
Delayed treatment of cynomolgus macaques with a FVM04/CA45 monoclonal antibody cocktail provides complete protection against lethal Sudan virus infection.
J Virol
August 2024
Special Pathogens program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Unlabelled: Sudan ebolavirus (SUDV) is a member of the genus (Family ) and has caused sporadic outbreaks of Ebola disease (EBOD), or more specifically Sudan virus disease (SVD), with high mortality rates in Africa. Current vaccines and therapies that have been developed for filoviruses are almost all specific for Ebola virus (EBOV; of the species ), and there is a current lack of therapeutics specific for SUDV. The recent SUDV outbreak in Uganda, which was distributed across multiple districts, including Kampala, a densely populated urban center, highlights the critical need for the development of novel SUDV-specific or pan-Ebola virus therapeutics.
View Article and Find Full Text PDFEbola virus (EBOV) is a high-consequence filovirus that gives rise to frequent epidemics with high case fatality rates and few therapeutic options. Here, we applied image-based screening of a genome-wide CRISPR library to systematically identify host cell regulators of Ebola virus infection in 39,085,093 million single cells. Measuring viral RNA and protein levels together with their localization in cells identified over 998 related host factors and provided detailed information about the role of each gene across the virus replication cycle.
View Article and Find Full Text PDFDesign and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
PLoS Pathog
April 2024
Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and/or to mitigate against viral escape by a single mutation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!